Department of Pediatric Rheumatology, Umraniye Training and Research Hospital, University of Health Sciences, Istanbul, Turkey.
Department of Pediatric Rheumatology, Kanuni Sultan Süleyman Training and Research Hospital, University of Health Sciences, Istanbul, Turkey.
Clin Rheumatol. 2021 Jun;40(6):2327-2337. doi: 10.1007/s10067-020-05492-8. Epub 2020 Nov 9.
INTRODUCTION/OBJECTIVES: The clinicians initially prefer to define patients with the systemic autoinflammatory disease (SAID)'s based on recommended clinical classification criteria; then, they confirm the diagnosis with genetic testing. We aimed to compare the initial phenotypic diagnoses of the patients who were followed up with the preliminary diagnosis of a monogenic SAID, and the genotypic results obtained from the next-generation sequence (NGS) panel.
Seventy-one patients with the preliminary diagnosis of cryopyrin-associated periodic fever syndrome (CAPS), mevalonate kinase deficiency (MKD), or tumor necrosis factor-alpha receptor-associated periodic fever syndrome (TRAPS) were included in the study. The demographic data, clinical findings, laboratory results, and treatments were recorded. All patients were examined by NGS panel analysis including 16 genes. The genetic results were compared with the initial Federici score to determine whether they were compatible with each other.
Thirty patients were initially classified as MKD, 22 as CAPS, and 19 as TRAPS. The frequency of clinical manifestations was urticarial rash 57.7%, diarrhea 49.2%, abdominal pain 47.8%, arthralgia 45%, oral aphthae 43.6%, myalgia 32.3%, tonsillitis 28.1%, and conjunctivitis 25.3%, respectively. After NGS gene panel screening, 13 patients were diagnosed with CAPS, 8 with MKD, 7 with familial Mediterranean fever, 5 with TRAPS, and 2 with NLRP12-associated periodic syndrome. The remaining 36 patients were genetically identified as undefined SAID since they were not classified as one of the defined SAIDs after the result of the NGS panel.
We have demonstrated that clinical diagnostic criteria may not always be sufficient to establish the correct diagnosis. There is still low accordance between clinical diagnoses and molecular analyses. In the case of a patient with a preliminary diagnosis of a monogenic SAID with the negative result of target gene analysis, other autoinflammatory diseases should also be kept in mind in the differential diagnosis. Key Points • Monogenic autoinflammatory diseases can present with different clinical manifestations. • The clinical diagnostic criteria may not always be sufficient to reach the correct diagnosis in autoinflammatory diseases. • In the case of a patient with a preliminary diagnosis of a monogenic SAID with the negative result of target gene analysis, other autoinflammatory diseases should be kept in mind in the differential diagnosis.
介绍/目的:临床医生最初倾向于根据推荐的临床分类标准来定义患有系统性自身炎症性疾病(SAID)的患者;然后,他们通过基因检测来确认诊断。我们旨在比较根据初步诊断为单基因 SAID 进行随访的患者的初始表型诊断,以及从下一代测序(NGS)面板获得的基因型结果。
本研究纳入了 71 例初步诊断为 Cryopyrin 相关周期性发热综合征(CAPS)、甲羟戊酸激酶缺乏症(MKD)或肿瘤坏死因子-α受体相关周期性发热综合征(TRAPS)的患者。记录了患者的人口统计学数据、临床发现、实验室结果和治疗情况。所有患者均接受了包括 16 个基因在内的 NGS 面板分析检查。将基因结果与初始 Federici 评分进行比较,以确定它们是否相符。
30 例患者最初被归类为 MKD,22 例为 CAPS,19 例为 TRAPS。临床表现的频率分别为荨麻疹 57.7%、腹泻 49.2%、腹痛 47.8%、关节炎 45%、口腔溃疡 43.6%、肌痛 32.3%、扁桃体炎 28.1%和结膜炎 25.3%。经过 NGS 基因面板筛查,13 例被诊断为 CAPS,8 例为 MKD,7 例为家族性地中海热,5 例为 TRAPS,2 例为 NLRP12 相关周期性综合征。其余 36 例患者由于在 NGS 面板结果后未被归类为已定义的 SAID 之一,因此在基因上被确定为未定义的 SAID。
我们已经证明,临床诊断标准可能并不总是足以确立正确的诊断。临床诊断和分子分析之间仍然存在低一致性。在初步诊断为单基因 SAID 的患者且靶基因分析结果为阴性的情况下,在鉴别诊断中还应考虑其他自身炎症性疾病。关键点•单基因自身炎症性疾病可能表现出不同的临床表现。•在自身炎症性疾病中,临床诊断标准可能并不总是足以做出正确的诊断。•在初步诊断为单基因 SAID 的患者且靶基因分析结果为阴性的情况下,在鉴别诊断中还应考虑其他自身炎症性疾病。